POLE and in situ carcinoma: In total, 96 adenomas and in situ carcinomas were analyzed for mutations in 11 genes (APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53).